Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 72

1.

Is 68Ga-DOTATATE the answer in lung carcinoid? : Case report and review of literature.

Bhoil A, Mittal BR, Gayana S, Kashyap R, Bhattacharya A, Singh N.

Lung India. 2012 Oct;29(4):378-80. doi: 10.4103/0970-2113.102839.

2.

Dual Tracer PET Imaging (68Ga-DOTATATE and 18F-FDG) Features in Pulmonary Carcinoid: Correlation with Tumor Proliferation Index.

Bhatkar D, Utpat K, Basu S, Joshi JM.

Indian J Nucl Med. 2017 Jan-Mar;32(1):39-41. doi: 10.4103/0972-3919.198476.

3.

A comparison of 68Ga-DOTATATE and 18F-FDG PET/CT in pulmonary neuroendocrine tumors.

Kayani I, Conry BG, Groves AM, Win T, Dickson J, Caplin M, Bomanji JB.

J Nucl Med. 2009 Dec;50(12):1927-32. doi: 10.2967/jnumed.109.066639. Epub 2009 Nov 12.

4.

Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors.

Wild D, Bomanji JB, Benkert P, Maecke H, Ell PJ, Reubi JC, Caplin ME.

J Nucl Med. 2013 Mar;54(3):364-72. doi: 10.2967/jnumed.112.111724. Epub 2013 Jan 7.

5.

The value of somatostatin receptor imaging with In-111 Octreotide and/or Ga-68 DOTATATE in localizing Ectopic ACTH producing tumors.

Özkan ZG, Kuyumcu S, Balköse D, Ozkan B, Aksakal N, Yılmaz E, Sanlı Y, Türkmen C, Aral F, Adalet I.

Mol Imaging Radionucl Ther. 2013 Aug;22(2):49-55. doi: 10.4274/Mirt.69775. Epub 2013 Aug 1.

6.

68Ga-DOTATATE PET/CT for the detection of inflammation of large arteries: correlation with18F-FDG, calcium burden and risk factors.

Li X, Samnick S, Lapa C, Israel I, Buck AK, Kreissl MC, Bauer W.

EJNMMI Res. 2012 Sep 27;2(1):52. doi: 10.1186/2191-219X-2-52.

8.

The role of 68Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on 111In-DTPA-octreotide scintigraphy.

Srirajaskanthan R, Kayani I, Quigley AM, Soh J, Caplin ME, Bomanji J.

J Nucl Med. 2010 Jun;51(6):875-82. doi: 10.2967/jnumed.109.066134. Epub 2010 May 19.

9.

Comparison of ⁶⁸Ga-DOTATATE PET-CT, ¹⁸F-FDG PET-CT and 99mTc-(V)DMSA scintigraphy in the detection of recurrent or metastatic medullary thyroid carcinoma.

Ozkan ZG, Kuyumcu S, Uzum AK, Gecer MF, Ozel S, Aral F, Adalet I.

Nucl Med Commun. 2015 Mar;36(3):242-50. doi: 10.1097/MNM.0000000000000240.

PMID:
25369749
10.

Quantitative and qualitative intrapatient comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: net uptake rate for accurate quantification.

Velikyan I, Sundin A, Sörensen J, Lubberink M, Sandström M, Garske-Román U, Lundqvist H, Granberg D, Eriksson B.

J Nucl Med. 2014 Feb;55(2):204-10. doi: 10.2967/jnumed.113.126177. Epub 2013 Dec 30.

11.

(68)Ga-DOTA-peptide: A novel molecular biomarker for nasopharyngeal carcinoma.

Khor LK, Loi HY, Sinha AK, Tong KT, Goh BC, Loh KS, Lu SJ.

Head Neck. 2016 Apr;38(4):E76-80. doi: 10.1002/hed.24164. Epub 2015 Aug 14.

PMID:
26275126
12.

68Ga-DOTATATE PET/CT, 99mTc-HYNIC-octreotide SPECT/CT, and whole-body MR imaging in detection of neuroendocrine tumors: a prospective trial.

Etchebehere EC, de Oliveira Santos A, Gumz B, Vicente A, Hoff PG, Corradi G, Ichiki WA, de Almeida Filho JG, Cantoni S, Camargo EE, Costa FP.

J Nucl Med. 2014 Oct;55(10):1598-604. doi: 10.2967/jnumed.114.144543. Epub 2014 Aug 28.

13.

Can complementary 68Ga-DOTATATE and 18F-FDG PET/CT establish the missing link between histopathology and therapeutic approach in gastroenteropancreatic neuroendocrine tumors?

Has Simsek D, Kuyumcu S, Turkmen C, Sanlı Y, Aykan F, Unal S, Adalet I.

J Nucl Med. 2014 Nov;55(11):1811-7. doi: 10.2967/jnumed.114.142224. Epub 2014 Oct 14.

14.

Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (DOTA-DPhe1,Tyr3-octreotate) and 18F-FDG.

Kayani I, Bomanji JB, Groves A, Conway G, Gacinovic S, Win T, Dickson J, Caplin M, Ell PJ.

Cancer. 2008 Jun;112(11):2447-55. doi: 10.1002/cncr.23469.

15.
16.

Multicenter comparison of 18F-FDG and 68Ga-DOTA-peptide PET/CT for pulmonary carcinoid.

Lococo F, Perotti G, Cardillo G, De Waure C, Filice A, Graziano P, Rossi G, Sgarbi G, Stefanelli A, Giordano A, Granone P, Rindi G, Versari A, Rufini V.

Clin Nucl Med. 2015 Mar;40(3):e183-9. doi: 10.1097/RLU.0000000000000641.

PMID:
25608152
17.

Measured human dosimetry of 68Ga-DOTATATE.

Walker RC, Smith GT, Liu E, Moore B, Clanton J, Stabin M.

J Nucl Med. 2013 Jun;54(6):855-60. doi: 10.2967/jnumed.112.114165. Epub 2013 Mar 20.

18.

68Ga-DOTATOC versus 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors.

Poeppel TD, Binse I, Petersenn S, Lahner H, Schott M, Antoch G, Brandau W, Bockisch A, Boy C.

J Nucl Med. 2011 Dec;52(12):1864-70. doi: 10.2967/jnumed.111.091165. Epub 2011 Nov 9.

19.

Comparison of (68)Ga-DOTATATE and (18)F-fluorodeoxyglucose PET/CT in the detection of recurrent medullary thyroid carcinoma.

Conry BG, Papathanasiou ND, Prakash V, Kayani I, Caplin M, Mahmood S, Bomanji JB.

Eur J Nucl Med Mol Imaging. 2010 Jan;37(1):49-57. doi: 10.1007/s00259-009-1204-z.

PMID:
19662413
20.

68Ga DOTATATE PET/CT of Non-FDG-Avid Pulmonary Metastatic Hemangiopericytoma.

Hung TJ, Macdonald W, Muir T, Celliers L, Al-Ogaili Z.

Clin Nucl Med. 2016 Oct;41(10):779-80. doi: 10.1097/RLU.0000000000001313.

PMID:
27454598

Supplemental Content

Support Center